Trial · NCT00701415
Results by group88
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 88
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 0.5 mg/kg | Zero (0) Skin GL-3 Score at Baseline | 18.8 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 1.0 mg/kg | Zero (0) Skin GL-3 Score at Baseline | 33.3 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 0.5 mg/kg | Zero (0) Skin GL-3 Score at Week 52 | 75 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 1.0 mg/kg | Zero (0) Skin GL-3 Score at Week 52 | 80 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 0.5 mg/kg | Zero (0) Skin GL-3 Score at Week 156 | 56.3 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 1.0 mg/kg | Zero (0) Skin GL-3 Score at Week 156 | 80 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 0.5 mg/kg | Zero (0) Skin GL-3 Score at Week 260 | 68.8 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 1.0 mg/kg | Zero (0) Skin GL-3 Score at Week 260 | 66.7 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 0.5 mg/kg | Mild (1) Skin GL-3 Score at Baseline | 6.3 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 1.0 mg/kg | Mild (1) Skin GL-3 Score at Baseline | 0 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 0.5 mg/kg | Mild (1) Skin GL-3 Score at Week 52 | 6.3 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 1.0 mg/kg | Mild (1) Skin GL-3 Score at Week 52 | 13.3 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 0.5 mg/kg | Mild (1) Skin GL-3 Score at Week 156 | 18.8 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 1.0 mg/kg | Mild (1) Skin GL-3 Score at Week 156 | 0 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 0.5 mg/kg | Mild (1) Skin GL-3 Score at Week 260 | 12.5 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 1.0 mg/kg | Mild (1) Skin GL-3 Score at Week 260 | 20 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 0.5 mg/kg | Moderate (2) Skin GL-3 Score at Baseline | 75 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 1.0 mg/kg | Moderate (2) Skin GL-3 Score at Baseline | 66.7 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 0.5 mg/kg | Moderate (2) Skin GL-3 Score at Week 52 | 0 | Percentage of participants | |
| Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium | Fabrazyme 1.0 mg/kg | Moderate (2) Skin GL-3 Score at Week 52 | 0 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00701415/results